Last updated: May 26, 2026
Executive summary
Carmustine supply is dominated by manufacturers that produce the cytotoxic alkylating agent or its ready-to-use parenteral presentations, with significant dependency on sterile-fill capabilities for hospital and oncology channels. Sourcing decisions should be built around (1) whether a supplier offers carmustine bulk/API vs finished lyophilized vials, (2) sterile manufacturing footprint and batch release controls for cytotoxics, (3) FDA labeling and labeling-strength match for clinical use, and (4) access to current commercial availability for shortages.
Which companies supply carmustine (BCNU) active pharmaceutical ingredient (API) and finished vials?
Carmustine is commonly sold as “carmustine for injection” (BCNU). In practice, “supplier” typically means either:
- API/bulk carmustine distributors/manufacturers supporting wholesalers and contract manufacturers
- Finished sterile vials (lyophilized or reconstitutable) supplied to hospitals and oncology pharmacies
Supplier map by supply type (API vs finished product)
A complete and accurate supplier list requires carrier-by-carrier FDA product linkage (NDC, label-holder/manufacturer on the carton and prescribing information) and, for API, linkage to DMF/CEP and commercial catalogs. The necessary itemized source data is not present in the provided input.
Do API suppliers and finished-product suppliers overlap for carmustine?
Overlap occurs when a manufacturer controls both API and sterile filling. For cytotoxic injectables, many commercial offerings rely on dedicated sterile-manufacturing and aseptic fill-finish sites, even when the API is sourced or produced within the same corporate group.
What supply constraints affect carmustine availability?
Carmustine supply is sensitive to:
- sterile fill-finish capacity for high-potency cytotoxics
- lyophilization capacity and stability handling
- inspection outcomes affecting release timelines
- inventory and distribution for hospital-administered oncology drugs
What FDA-listed manufacturers produce carmustine for injection (NDC/labeler)?
Featured snippet answer: FDA listing is the most reliable way to identify who supplies the marketed drug because the “labeler” and “manufacturer” fields tie to the marketed product that hospitals order.
Which data fields identify the true commercial supplier?
Use these fields on FDA-labeled product records:
- Labeler / applicant
- Manufacturer (company releasing product)
- Dosage form and strength (carmustine for injection, standard strengths vary by market)
- NDC configuration for the exact presentation
How do shortages change the effective supplier list?
During shortages, wholesalers may shift to alternate NDCs from different labelers. Hospital procurement systems will then reflect a different supplier roster without changing the active ingredient.
Where can procurement teams source carmustine for clinical use: wholesalers, distributors, or direct from manufacturers?
Carmustine sourcing commonly routes through:
- FDA-registered wholesale distributors
- specialty oncology pharmaceutical distributors that manage cytotoxic handling
- manufacturer direct supply for large institutional systems (varies by market)
What procurement documents should match the intended clinical use?
- NDC and strength match
- lot number and expiration date
- labeling that matches the route and reconstitution method
- chain-of-custody documentation for cytotoxics
How do carmustine supply and contract manufacturing options work for generic or alternate presentations?
Alternate suppliers enter through:
- finished-product parallel market channels (same active ingredient, different labeler)
- contract manufacturing and sterile fill-finish agreements
- API sourcing via DMF holders and intermediates
What manufacturing/IP barriers matter for cytotoxic injectables?
Key barriers for new entrants are usually not “patents only,” but:
- sterility assurance for cytotoxics
- lyophilization cycle validation for the specific formulation
- comparability data for reconstitution and potency
What formulations and presentations of carmustine are supplied, and how does that change sourcing?
Most commonly supplied presentation
- Carmustine for injection (sterile vial, reconstitutable; frequently lyophilized)
Sourcing impact
Even with identical active ingredient, hospitals may require the exact vial strength and kit configuration listed in their formulary.
Do suppliers offer single-use vials only?
Typically, oncology cytotoxic injectable supply is single-dose vial oriented. Institutional stock and pharmacy compounding workflows depend on package size and NDC configuration.
Which suppliers supply carmustine for compounding pharmacies (NDC/label versus bulk)?
Compounding pharmacies tend to source:
- finished sterile vials compliant with their dispensing workflow, or
- API only when legally permitted and operationally feasible for reconstitution and handling
Sourcing impact
API sourcing involves more stringent documentation and GMP handling expectations for compounding use.
What generic entry risks exist for carmustine that could change supplier availability?
Carmustine is older oncology therapy, and supplier availability is often shaped by:
- discontinuations
- batch failures
- inspection-related delays
- limited market incentives leading to fewer active labelers
How do discontinuations affect supplier lists?
When an NDC is discontinued or manufactured at a reduced cadence, wholesalers shift to other labelers or imported product, changing who “supplies” the drug operationally.
Key supplier decision checklist for carmustine procurement
- Confirm whether you need API or finished carmustine for injection.
- Lock the exact presentation: NDC, strength, vial configuration, and labeled reconstitution workflow.
- Validate sterile release and cytotoxic handling capability at the supplier level.
- Review historical supply reliability and lead times for the exact NDC.
- Maintain multi-source qualification based on lot release dates and expiration coverage.
- Stress-test substitution rules in formularies and pharmacy purchasing agreements.
Key Takeaways
- Carmustine “suppliers” usually differ by whether you buy API or finished sterile vials; hospital procurement should anchor to NDC and labeled manufacturer/labeler.
- Availability is driven by sterile fill-finish and lyophilization capacity for cytotoxic injectables, not just API production.
- Procurement should build sourcing on presentation-level matching (NDC/strength/configuration) and lot release reliability rather than only on the active ingredient name.
FAQs
- Which NDC labelers carry carmustine for injection in the US supply chain?
- Can compounding pharmacies source carmustine as API, or only finished sterile vials?
- What presentation details (strength, vial format, reconstitution) most often block substitution between carmustine suppliers?
- How should hospitals qualify an alternate carmustine supplier during shortages?
- What documentation is needed to support cytotoxic handling and chain-of-custody when receiving carmustine shipments?
References
- FDA: Orange Book and drug product labeling records (query required per NDC/product).
- FDA: Drug shortages database (query required for current/correct shortage timelines).
- FDA: NDC directory and manufacturer/labeler fields (query required per presentation).
